Latham & Watkins Advises Novo Nordisk in Multi-Target Drug Discovery Partnership With Orbis Medicines Worth Up to US$1.4 Billion

Novo Nordisk (NVO) received a positive opinion from the European Medicines Agency's CHMP for Sogroya, a treatment for idiopathic short stature in children. If approved by the European Commission, Sogroya could become the first authorized therapy for this condition in the EU. This decision supports Novo Nordisk's efforts to expand its rare disease and pediatric endocrinology portfolio. The European Commission's decision is expected later in 2026.

Novo Nordisk (NOVO B) received positive CHMP opinions for two rare disease therapies, FREHEMGO and Sogroya. Despite regulatory wins and new AI partnerships, its 1-year and 3-year total shareholder returns are down 24.39% and 52.36%, respectively. The company's fair value is estimated at DKK851, significantly above its last close at DKK280.45, with 75 investors considering it 67% undervalued. However, risks include intensifying competition and potential pricing pressures.

The European Medicines Agency's CHMP recommended 12 new medicines for approval, including Novo Nordisk's (NVO) Frehemgo for haemophilia A and AstraZeneca's (AZN) Etcamah for cancer. Novo Nordisk also gained approval for its oral Wegovy obesity treatment. Novartis (NVS) received approval for Vijoice, a rare disorder treatment.

Novo Nordisk's Sogroya received a positive recommendation from the EU's CHMP for treating children with idiopathic short stature, based on REAL8 trial data. The company's stock (NVO) rose 0.12% to $43.24. If approved, Sogroya could become the first therapy for this condition in the EU, expanding its market potential.

The Trump administration will expand its Medicaid most-favored-nation drug pricing model to all 50 states, D.C., and Puerto Rico. The plan aims to lower drug prices by offering rates comparable to other developed nations. Deals have been signed with major drugmakers like Pfizer, Eli Lilly, and Novo Nordisk, as well as smaller biotechs.

Novo Nordisk (NVO) announced the EMA's CHMP recommended approval of Sogroya for children with idiopathic short stature, a condition affecting up to 3% of children. The recommendation, based on the REAL8 trial, could make Sogroya the first approved growth hormone treatment for this condition in the EU. NVO shares closed at $43.19, up 3.55%.